Document is current
Any future updates will be listed below
-
Authors
van Sleen, Yannick https://orcid.org/0000-0002-7382-8322
Therkildsen, Philip
Nielsen, Berit Dalsgaard
van der Geest, Kornelis S. M.
Hansen, Ib
Heeringa, Peter
Posthumus, Marcel D.
Sandovici, Maria
Toonen, Erik J. M.
Zijlstra, Jannik
Boots, Annemieke M. H.
Hauge, Ellen-Margrethe
Brouwer, Elisabeth
- License Information
-
More Information
Article History
Received: 20 December 2021
Accepted: 1 February 2022
First Online: 7 March 2022
Declarations
:
: Written informed consent was obtained from all study participants, and all procedures were in compliance with the Declaration of Helsinki. For the AGP cohort, approval from The Central Denmark Region Committees on Health Research Ethics (reference number 1-10-72-60-14) was obtained. For the GPS cohort, including infection controls, approval from the institutional review board was obtained (METc2010/22). For the HCs, approval from the institutional review board was also obtained (METc2012/375).
: The authors declare that they have no competing interests. EB and KvdG as employees of the UMCG received speaker/consulting fees from Roche which were paid to the UMCG. PH and EB have received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement 668036. ET is an employee of Hycult Biotech. BDN has received fees for speaking and/or consulting from Roche and Sanofi. EH has received fees for speaking and/or consulting from AbbVie, Sanofi, Sobi, MSD and UCB; research funding to Aarhus University Hospital from Novo Nordic Foundation, Danish Rheumatism Association, Danish Regions Medicine Grants, Roche and Norvartis; and travel expenses from Celgene, MSD, Pfizer, Roche and Sobi.
